NCT00572793View on ClinicalTrials.gov

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

CompletedOBSERVATIONAL
Enrollment

431

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Preeclampsia
Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors
All Listed Sponsors
collaborator

Diagnostic Technologies Ltd.

INDUSTRY

lead

Carl Weiner, MD

OTHER